MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
Status:
Completed
Trial end date:
2013-04-09
Target enrollment:
Participant gender:
Summary
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard
of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).